{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:08:38Z","timestamp":1791443318072,"version":"4.3.3"},"reference-count":32,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Most patients with solitary bone plasmacytomas (SBP) progress to multiple myeloma (MM) after definitive radiation therapy as their primary treatment. Whether the presence of high-risk (HR) cytogenetic abnormalities by fluorescence in situ hybridization (FISH) in the clonal plasma cells, obtained either directly from the diagnostic SBP tissue or the corresponding bone marrow examination at the time of diagnosis, is associated with a shorter time to progression (TTP) to MM is unknown. This study evaluated all patients diagnosed with SBP at the Mayo Clinic from January 2012 to July 2022. The presence of del(17p), t(14;16), t(4;14), or\u00a0+1q (gain or amplification) by FISH in clonal plasma cells was defined as HR. A total of 114 patients were included in this cohort, and baseline FISH was available for 55 patients (48%), of which 22 were classified as HR (40%). The median TTP to MM for patients with SBP and HR FISH was 8 months (95% confidence interval [CI], 6.3-26) compared with 42 months (95% CI, 25-not reached [NR]) in patients with SBP without HR FISH (P\u00a0&amp;lt; .001). In a multivariate analysis, only HR FISH was a significant predictor for shorter TTP to MM, independent of minimal marrow involvement and an abnormal serum free light chain ratio at diagnosis. Deletion (17p) and\u00a0gain 1q abnormalities were the most common FISH abnormalities responsible for the short TTP to MM. Thus, assessing for HR FISH abnormalities in clonal plasma cells derived from either the diagnostic SBP tissue or the staging bone marrow examination of patients with newly diagnosed SBP is feasible and prognostic for a shorter TTP to MM.<\/jats:p>","DOI":"10.1182\/blood.2023021187","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T21:05:24Z","timestamp":1690405524000},"page":"1871-1878","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":16,"title":["Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas"],"prefix":"10.1182","volume":"142","author":[{"given":"Udit","family":"Yadav","sequence":"first","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji K.","family":"Kumar","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda B.","family":"Baughn","sequence":"additional","affiliation":[{"name":"2Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8780-9512","authenticated-orcid":false,"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5536-9011","authenticated-orcid":false,"given":"Patricia","family":"Greipp","sequence":"additional","affiliation":[{"name":"2Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhett","family":"Ketterling","sequence":"additional","affiliation":[{"name":"2Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragan","family":"Jevremovic","sequence":"additional","affiliation":[{"name":"2Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3214-0203","authenticated-orcid":false,"given":"Francis K.","family":"Buadi","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dingli","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1193-1559","authenticated-orcid":false,"given":"Martha Q.","family":"Lacy","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[{"name":"3Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1523-7388","authenticated-orcid":false,"given":"P. Leif","family":"Bergsagel","sequence":"additional","affiliation":[{"name":"3Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sikander","family":"Ailawadhi","sequence":"additional","affiliation":[{"name":"4Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5950-4620","authenticated-orcid":false,"given":"Vivek","family":"Roy","sequence":"additional","affiliation":[{"name":"4Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9314-9933","authenticated-orcid":false,"given":"Ricardo","family":"Parrondo","sequence":"additional","affiliation":[{"name":"4Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taimur","family":"Sher","sequence":"additional","affiliation":[{"name":"4Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne R.","family":"Hayman","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5651-1411","authenticated-orcid":false,"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"},{"name":"5Division of Nephrology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5335-9533","authenticated-orcid":false,"given":"Joselle","family":"Cook","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9014-9658","authenticated-orcid":false,"given":"Moritz","family":"Binder","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2210-2174","authenticated-orcid":false,"given":"Eli","family":"Muchtar","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0240-0326","authenticated-orcid":false,"given":"Rahma","family":"Warsame","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8573-9434","authenticated-orcid":false,"given":"Taxiarchis V.","family":"Kourelis","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald S.","family":"Go","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Seth","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott C.","family":"Lester","sequence":"additional","affiliation":[{"name":"6Department of Radiation Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Breen","sequence":"additional","affiliation":[{"name":"6Department of Radiation Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Kyle","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson I.","family":"Gonsalves","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"12","key":"2023113016210889000_bib1","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"2023113016210889000_bib2","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1365-2141.2008.07421.x","article-title":"Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992-2004","volume":"144","author":"Dores","year":"2009","journal-title":"Br J Haematol"},{"issue":"6","key":"2023113016210889000_bib3","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/s41375-018-0099-8","article-title":"Treatment approaches and outcomes in plasmacytomas: analysis using a national dataset","volume":"32","author":"Goyal","year":"2018","journal-title":"Leukemia"},{"issue":"4","key":"2023113016210889000_bib4","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ijrobp.2018.05.009","article-title":"radiation therapy for solitary plasmacytoma and multiple myeloma: guidelines from the International Lymphoma Radiation Oncology Group","volume":"101","author":"Tsang","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2023113016210889000_bib5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13045-017-0549-1","article-title":"Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel","volume":"11","author":"Caers","year":"2018","journal-title":"J\u00a0Hematol Oncol"},{"issue":"4","key":"2023113016210889000_bib6","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/bjh.14291","article-title":"Progression of a solitary plasmacytoma to multiple myeloma. a population-based registry of the northern Netherlands","volume":"175","author":"de Waal","year":"2016","journal-title":"Br J Haematol"},{"issue":"4","key":"2023113016210889000_bib7","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/bjh.13870","article-title":"Clinical features and prognostic factors in solitary plasmacytoma","volume":"172","author":"Finsinger","year":"2016","journal-title":"Br J Haematol"},{"issue":"8","key":"2023113016210889000_bib8","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/ajh.23745","article-title":"Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek Myeloma Study Group in 97 patients","volume":"89","author":"Katodritou","year":"2014","journal-title":"Am J Hematol"},{"key":"2023113016210889000_bib9","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1471-2407-6-118","article-title":"Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study","volume":"6","author":"Knobel","year":"2006","journal-title":"BMC Cancer"},{"issue":"1","key":"2023113016210889000_bib10","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ijrobp.2005.06.039","article-title":"Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients","volume":"64","author":"Ozsahin","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"2023113016210889000_bib11","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/ajh.23201","article-title":"Trends and outcomes of modern staging of solitary plasmacytoma of bone","volume":"87","author":"Warsame","year":"2012","journal-title":"Am J Hematol"},{"issue":"8","key":"2023113016210889000_bib12","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1182\/blood-2014-04-566521","article-title":"Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis","volume":"124","author":"Hill","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2023113016210889000_bib13","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1182\/blood-2014-04-567909","article-title":"Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma","volume":"124","author":"Paiva","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2023113016210889000_bib14","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1182\/blood-2006-04-015784","article-title":"Immunoglobulin free light chains and solitary plasmacytoma of bone","volume":"108","author":"Dingli","year":"2006","journal-title":"Blood"},{"issue":"5","key":"2023113016210889000_bib15","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood-2002-08-2441","article-title":"Prognostic value of angiogenesis in solitary bone plasmacytoma","volume":"101","author":"Kumar","year":"2003","journal-title":"Blood"},{"issue":"5","key":"2023113016210889000_bib16","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/cncr.10366","article-title":"Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone","volume":"94","author":"Wilder","year":"2002","journal-title":"Cancer"},{"issue":"2","key":"2023113016210889000_bib17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41408-021-00419-1","article-title":"Serum paraprotein persistence and size determine outcome in a cohort of patients with a modern definition of plasmacytoma with up to 19 years of follow up","volume":"11","author":"Manasanch","year":"2021","journal-title":"Blood Cancer J"},{"issue":"4","key":"2023113016210889000_bib18","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3324\/haematol.12005","article-title":"Primary extramedullary plasmacytoma: similarities with and differences from multiple myeloma revealed by interphase cytogenetics","volume":"93","author":"Bink","year":"2008","journal-title":"Haematologica"},{"issue":"5","key":"2023113016210889000_bib19","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1365-2141.2010.08386.x","article-title":"Extramedullary plasmacytoma are characterized by a 'myeloma-like' immunophenotype and genotype and occult bone marrow involvement","volume":"151","author":"Boll","year":"2010","journal-title":"Br J Haematol"},{"issue":"1","key":"2023113016210889000_bib20","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41408-023-00832-8","article-title":"Utility of flow cytometry screening before MRD testing in multiple myeloma","volume":"13","author":"Panakkal","year":"2023","journal-title":"Blood Cancer J"},{"issue":"24","key":"2023113016210889000_bib21","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"issue":"8","key":"2023113016210889000_bib22","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/leu.2013.86","article-title":"Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma","volume":"27","author":"Rajkumar","year":"2013","journal-title":"Leukemia"},{"issue":"10","key":"2023113016210889000_bib23","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)","volume":"10","author":"Mateos","year":"2020","journal-title":"Blood Cancer J"},{"issue":"34","key":"2023113016210889000_bib24","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1200\/JCO.2012.48.4923","article-title":"Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load","volume":"31","author":"Neben","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"2023113016210889000_bib25","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1182\/bloodadvances.2020002218","article-title":"Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities","volume":"4","author":"Abdallah","year":"2020","journal-title":"Blood Adv"},{"issue":"12","key":"2023113016210889000_bib26","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-019-0254-0","article-title":"Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone","volume":"9","author":"Schmidt","year":"2019","journal-title":"Blood Cancer J"},{"issue":"7","key":"2023113016210889000_bib27","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.3324\/haematol.2009.016436","article-title":"Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation","volume":"95","author":"Neben","year":"2010","journal-title":"Haematologica"},{"issue":"1","key":"2023113016210889000_bib28","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1038\/s41467-022-32145-y","article-title":"The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states","volume":"13","author":"Rasche","year":"2022","journal-title":"Nat Commun"},{"key":"2023113016210889000_bib29","article-title":"Chemotherapy in solitary bone plasmacytoma to prevent evolution to multiple myeloma","author":"Ascione","year":"23  2023","journal-title":"Haematologica"},{"issue":"22","key":"2023113016210889000_bib30","doi-asserted-by":"crossref","first-page":"4514-4514","DOI":"10.1182\/blood.V128.22.4514.4514","article-title":"Adjuvant chemotherapy in the treatment of solitary bone plasmacytoma","volume":"128","author":"Mheidly","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2023113016210889000_bib31","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ijrobp.2019.10.043","article-title":"Solitary plasmacytoma treated by lenalidomide-dexamethasone in combination with radiation therapy: clinical outcomes","volume":"106","author":"Mignot","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2023113016210889000_bib32","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1038\/s41467-018-05058-y","article-title":"Genomic patterns of progression in smoldering multiple myeloma","volume":"9","author":"Bolli","year":"2018","journal-title":"Nat Commun"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/22\/1871\/2091073\/blood_bld-2023-021187-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/22\/1871\/2091073\/blood_bld-2023-021187-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T16:21:36Z","timestamp":1701361296000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/142\/22\/1871\/497114\/Impact-of-cytogenetic-abnormalities-on-the-risk-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,30]]},"references-count":32,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2023,11,30]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023021187","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,30]]}}}